SEARCH OUR PRODUCT CATALOG

BIRC2-YAP1 Fusion FISH Probe

The BIRC2-YAP1 Fusion FISH Probe is used to confirm a fusion of the BIRC2 and YAP1 genes. The fusion of the BIRC2 and YAP1 genes has been associated with Stomach Adenocarcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.

** This product is for in vitro and research use only. This product is not intended for diagnostic use. Please note that both genes fall on the same chromosome and inter-chromosomal detection may be difficult to detect depending on the genes proximity to one another. Please consult our support staff before ordering this product to ensure that the probe can be designed to meet your specific needs.

Turnaround Time: 7-10 Business Days    Shipping Time: 1-2 Day Expedited Shipping

SKU Test Kits Buffer Dye Color Order Now
BIRC2-YAP1-20-ORGR  (Standard Design) 20 (40 μL) 200 μL
BIRC2-YAP1-20-RERE 20 (40 μL) 200 μL
BIRC2-YAP1-20-REOR 20 (40 μL) 200 μL
BIRC2-YAP1-20-REGO 20 (40 μL) 200 μL
BIRC2-YAP1-20-REGR 20 (40 μL) 200 μL
BIRC2-YAP1-20-REAQ 20 (40 μL) 200 μL
BIRC2-YAP1-20-ORRE 20 (40 μL) 200 μL
BIRC2-YAP1-20-OROR 20 (40 μL) 200 μL
BIRC2-YAP1-20-ORGO 20 (40 μL) 200 μL
BIRC2-YAP1-20-ORAQ 20 (40 μL) 200 μL
BIRC2-YAP1-20-GORE 20 (40 μL) 200 μL
BIRC2-YAP1-20-GOOR 20 (40 μL) 200 μL
BIRC2-YAP1-20-GOGO 20 (40 μL) 200 μL
BIRC2-YAP1-20-GOGR 20 (40 μL) 200 μL
BIRC2-YAP1-20-GOAQ 20 (40 μL) 200 μL
BIRC2-YAP1-20-GRRE 20 (40 μL) 200 μL
BIRC2-YAP1-20-GROR 20 (40 μL) 200 μL
BIRC2-YAP1-20-GRGO 20 (40 μL) 200 μL
BIRC2-YAP1-20-GRGR 20 (40 μL) 200 μL
BIRC2-YAP1-20-GRAQ 20 (40 μL) 200 μL
BIRC2-YAP1-20-AQRE 20 (40 μL) 200 μL
BIRC2-YAP1-20-AQOR 20 (40 μL) 200 μL
BIRC2-YAP1-20-AQGO 20 (40 μL) 200 μL
BIRC2-YAP1-20-AQGR 20 (40 μL) 200 μL
BIRC2-YAP1-20-AQAQ 20 (40 μL) 200 μL

BIRC2 Gene Summary

The protein encoded by this gene is a member of a family of proteins that inhibits apoptosis by binding to tumor necrosis factor receptor-associated factors TRAF1 and TRAF2, probably by interfering with activation of ICE-like proteases. This encoded protein inhibits apoptosis induced by serum deprivation and menadione, a potent inducer of free radicals. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jan 2012]

Gene Name: Baculoviral IAP Repeat Containing 2

Chromosome: CHR11: 102217965 -102249401

Locus: 11q22.2

YAP1 Gene Summary

This gene encodes a downstream nuclear effector of the Hippo signaling pathway which is involved in development, growth, repair, and homeostasis. This gene is known to play a role in the development and progression of multiple cancers as a transcriptional regulator of this signaling pathway and may function as a potential target for cancer treatment. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Aug 2013]

Gene Name: Yes Associated Protein 1

Chromosome: CHR11: 101981191 -102104154

Locus: 11q22.1

Gene Diseases

The BIRC2 YAP1 Fusion has been associated with the following diseases:

Disease Name
Stomach Adenocarcinoma

FISH Probe Protocols

Protocol, Procedure, or Form Name Last Modified Download

Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging

Ependymoma is a tumor of the central nervous system that can exhibit fusion of the RELA gene. Diagnosing these accurately is important, and can be done with FISH, IHC, or DNA methylation. FISH analysis was performed with RELA break apart probes (RP11_58D3 and RP11_436C17/RP11_1104L6). MN1 and YAP1 break apart probes were also used in conjunction with the DNA methylation.

Childhood supratentorial ependymomas with YAP1_MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features

Ependymoma is a tumor that arises from tissue of the nervous system. Rare cases involve a YAP1/MAMLD1 fusion that can occur in childhood. This study sought to expand on the unique clinical features of neoplasms harboring this fusion. Our YAP1 break apart probe was used to detect YAP1 gene rearrangements in several of the cases under study. It was determined that YAP1/MAMLD1 fusion ependymomas display characteristics that distinct from RELA fusion ependymomas.